Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 2/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | DUT | P33316 | 3/20 | 0.37 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.36 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800653 | 0.82 | P2RY2 (0.51) | P2RY2P2RY4CYP3A4CYP2C9DUT | |
| SCHEMBL20427387 | 0.82 | P2RY2 (0.51) | P2RY2P2RY4CYP3A4CYP2C9DUT | |
| SCHEMBL383248 | 0.82 | P2RY2 (0.51) | P2RY2P2RY4CYP3A4CYP2C9DUT | |
| SCHEMBL800821 | 0.82 | P2RY2 (0.51) | P2RY2P2RY4CYP3A4CYP2C9DUT | |
| SCHEMBL2552431 | 0.81 | P2RY2 (0.50) | P2RY2P2RY4CYP3A4CYP2C9DUT | |
| SCHEMBL3866779 | 0.78 | SLC28A1 (0.52) | P2RY2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL20822313 | 0.77 | CYP3A4 (0.38) | P2RY2P2RY4CYP3A4CYP2C9NT5E | |
| SCHEMBL2014365 | 0.77 | CYP3A4 (0.38) | P2RY2P2RY4CYP3A4CYP2C9NT5E | |
| SCHEMBL9221120 | 0.77 | NT5E (0.36) | P2RY2P2RY4CYP3A4CYP2C9NT5E | |
| SCHEMBL6256517 | 0.77 | NT5E (0.36) | P2RY2P2RY4CYP3A4CYP2C9NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2319853-B1 | Process for the production of 2'-branched nucleosides | IDENIX PHARMACEUTICALS INC (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2319853-A1 | Process for the production of 2'-branched nucleosides | Idenix (Cayman) Limited (KY) | 2011-05-11 | — | — | EP | disclosed |
| US-7598373-B2 | Process for the production of 2-C-methyl-D-ribonolactone | IDENIX PHARMACEUTICALS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1585529-A4 | PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES | IDENIX CAYMAN LTD (KY) | 2008-05-28 | — | — | EP | disclosed |
| EP-1585529-A2 | PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES | Idenix (Cayman) Limited (KY) | 2005-10-19 | — | — | EP | disclosed |
| US-20050020825-A1 | Process for the production of 2'-branched nucleosides | IDENIX PHARMACEUTICALS LLC | 2005-01-27 | — | — | US | disclosed |
| WO-2004052899-A2 | PROCESS FOR THE PRODUCTION OF 2'-BRANCHED NUCLEOSIDES | IDENIX (CAYMAN) LIMITED (KY) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020825-A1 | Process for the production of 2'-branched nucleosides | RNGTT, MTAP, NSUN2 | P2RY2 1660/4885P2RY4 1251/4885CYP3A4 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.